{{Rsnum
|rsid=6721498
|Gene=NRXN1
|Chromosome=2
|position=50485874
|Orientation=plus
|GMAF=0.4844
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NRXN1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 21.5 | 60.0 | 18.5
| HCB | 26.7 | 44.4 | 28.9
| JPT | 18.2 | 45.5 | 36.4
| YRI | 36.5 | 39.7 | 23.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 26.7 | 44.4 | 28.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs6721498]] has been reported to be associated with increased risk for nicotine dependence. {{PMID|18270208|OA=1
}}

{{PharmGKB
|RSID=rs6721498
|Name_s=
|Gene_s=NRXN1
|Feature=
|Evidence=PubMed ID:18270208
|Annotation=A study on 2037 individuals from 602 nuclear families of African-American or European-American origin found a significant associations of this SNP in the NRXN1 gene with smoking quantity, the heaviness of smoking index and the Fagerstr?m test for nicotine dependence in the African-American sample.
|Drugs=nicotine
|Drug Classes=
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA162316627
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6721498
|overall_frequency_n=59
|overall_frequency_d=128
|overall_frequency=0.460938
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}